GeneThera to Complete Additional Audit of Financials
15 Janeiro 2009 - 5:51PM
Marketwired
GeneThera, Inc. (PINKSHEETS: GTHR) announced today its intention to
maintain its status as Sarbanes-Oxley compliant. The company's
Auditor, W. T. Uniack & Co. CPAs, should have the audit
completed in February.
Although GeneThera is already a fully reporting company, it has
elected to re-audit all of its prior financial statements due to
the revocation of its previous auditors' PCAOB registration. This
re-audit is also a condition of any future buyout or merger
agreement.
GeneThera has maintained all financial reporting as required by
Sarbanes-Oxley in order to have its trading status upgraded to
NASDAQ requirements.
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in
Wheat Ridge, Colorado. The Company's proprietary diagnostic
solution is based on a genetic expression assay, GES(TM), a
protocol designed to function on a highly automated Fluorogenic PCR
platform. This platform enables GeneThera to offer tests that are
presently not available from other technologies. The GES is
designed for a host of individual diseases, the current priorities
being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For
more information, contact Al Goldsmith of The Goldsmith Group LLC
at 303-463-6371 Ext. 206.
This press release contains forward-looking statements, which
are made pursuant to the Safe-Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as "intends,"
"believes," and similar expressions reflecting something other than
historical fact are intended to identify forward-looking
statements, but are not the exclusive means of identifying such
statements. These forward-looking statements involve a number of
risks and uncertainties, including the timely development and
market acceptance of products and technologies, the ability to
secure additional sources of finance, the ability to reduce
operating expenses, and other factors described in the Company's
filings with the Securities and Exchange Commission. The actual
results that the Company achieves may differ materially from any
forward-looking statement due to such risks and uncertainties. The
Company undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or
circumstances that may arise after the date of this release.
Dr. Tony Milici 303-463-6371 Goldsmith Group 303-838-4370 JR
Dopkin & Associates 516-884-3200
GeneThera (CE) (USOTC:GTHR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
GeneThera (CE) (USOTC:GTHR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre GeneThera Inc (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de GeneThera